2021
DOI: 10.1021/acsabm.1c00732
|View full text |Cite
|
Sign up to set email alerts
|

Microfluidics for Development of Lipid Nanoparticles: Paving the Way for Nucleic Acids to the Clinic

Abstract: Nucleic acid therapeutics hold an unprecedented promise toward treating many challenging diseases; however, their use is hampered by delivery issues. Microfluidics, dealing with fluids in the microscale dimensions, have provided a robust means to screening raw materials for development of nano delivery vectors, in addition to controlling their size and minimizing their polydispersity. In this mini-review, we are briefly highlighting the different types of nucleic acid therapies with emphasis on the delivery re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
17
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(18 citation statements)
references
References 80 publications
0
17
0
1
Order By: Relevance
“…Remote loading methods have allowed us to work on smaller scale than older organo-chemical methods, which for example, may involve flash evaporators. However, newer microfluidic methods are scalable and microfluidics simplifies and speeds up the assembly of various types of lipid nanoparticles from constituent lipids and almost any class of drug beyond remote loading methods [ 45 , 46 ]. Indeed Pfizer’s and Moderna’s Spike mRNA lipid nanoparticle vaccines are both produced using microfluidic methods [ 47 ].…”
Section: Discussionmentioning
confidence: 99%
“…Remote loading methods have allowed us to work on smaller scale than older organo-chemical methods, which for example, may involve flash evaporators. However, newer microfluidic methods are scalable and microfluidics simplifies and speeds up the assembly of various types of lipid nanoparticles from constituent lipids and almost any class of drug beyond remote loading methods [ 45 , 46 ]. Indeed Pfizer’s and Moderna’s Spike mRNA lipid nanoparticle vaccines are both produced using microfluidic methods [ 47 ].…”
Section: Discussionmentioning
confidence: 99%
“…Protecting cationic liposomes using hydrophilic molecules, such as poly (ethylene glycol) (PEG), have been used to extend their circulation and reduce inflammatory responses as they reduce phagocytic opsonization activity (Qelliny et al, 2021). SNALPs are among the PEGylated cationic liposomes that provide hydrophilicity and a neutral layer to stabilize these particles in circulation (Ali et al, 2021). An exciting feature of SNALPs is that they show a positive charge at acidic pH while neutral at physiological pH (Rudorf & Rädler, 2012).…”
Section: Sirnas Nano‐delivery Systemsmentioning
confidence: 99%
“…Dichloromethane, tetrahydrofuran, and chloroform can be used for glass. All these devices can produce narrow-distribution small-sized LNPs . However, the chaotic mixer device is most widely used to prepare mRNA-LNPs .…”
Section: Challenges For Mrna Delivery Nanoplatformsmentioning
confidence: 99%